EZ Cap™ Mouse CD137 mRNA (m1Ψ, HA tag)

CD137, also known as 4-1BB, is an important immunomodulatory molecule that belongs to the tumor necrosis factor receptor (TNFR) superfamily. It is mainly expressed on activated T cells, natural killer cells (NK cells) and dendritic cells. The ligand for CD137 is 4-1BBL, which is mainly expressed on antigen-presenting cells. Activation of CD137 can enhance the proliferation and survival of T cells and promote the secretion of cytokines such as IFN-γ and IL-2, thereby enhancing the immune response. This property makes CD137 an important target for cancer immunotherapy, where activation of CD137 can enhance the anti-tumor immune response. In addition, the CD137 signaling pathway also plays a complex role in autoimmune diseases and transplant rejection.

EZ Cap™ Mouse CD137 mRNA (m1Ψ, HA tag) is provided at a concentration of ~1 mg/ml with Cap1 structure. It expresses Mouse CD137 cytokine with HA label, which is convenient for the subsequent detection of protein expression. There are currently two ways to cap mRNA: One is co-transcription method, by adding Cap analogues into the transcription process. The other is enzymatic Capping. After transcription, Cap0 capping is performed by Vaccinia virus Capping Enzyme (VCE), GTP and S-adenosylmethionine (SAM). The Cap0 is then generated into the Cap1 through 2´-O-Methyltransferase and SAM. Cap1 Capping can also be performed by adding VCE, 2´-O-Methyltransferase, GTP and SAM in a one-step process. Cap 1 structure is more ideal for mammalian systems and possess higher transcription efficiency than Cap 0 structure. The addition of N1-Methylpseudo-UTP(m1Ψ) and poly(A) tail suppress RNA-mediated innate immune activation and increase the stability and lifetime of the mRNA in vitro and in vivo. Poly(A) tail also plays an important role in enhancing the efficiency of translation initiation.